<code id='F0A55A09E8'></code><style id='F0A55A09E8'></style>
      • <acronym id='F0A55A09E8'></acronym>
      <center id='F0A55A09E8'><center id='F0A55A09E8'><tfoot id='F0A55A09E8'></tfoot></center><abbr id='F0A55A09E8'><dir id='F0A55A09E8'><tfoot id='F0A55A09E8'></tfoot><noframes id='F0A55A09E8'>
      • <optgroup id='F0A55A09E8'><strike id='F0A55A09E8'><sup id='F0A55A09E8'></sup></strike><code id='F0A55A09E8'></code></optgroup>
        5. <b id='F0A55A09E8'><label id='F0A55A09E8'><select id='F0A55A09E8'><dt id='F0A55A09E8'><span id='F0A55A09E8'></span></dt></select></label></b><u id='F0A55A09E8'></u>
          <i id='F0A55A09E8'><strike id='F0A55A09E8'><tt id='F0A55A09E8'><pre id='F0A55A09E8'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-27 10:27:17 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：2
                                  
                                    
          
                                   
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan.																									Courtesy Secrist family 
          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.
          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 
          advertisement
          “Oh, crap,” Secrist said to herself.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          CRISPR pioneers react to Casgevy, first gene
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles